小细胞肺癌c-kit蛋白表达及小细胞肺癌化疗后维持治疗探讨

c-kit蛋白受体是跨膜酪氨酸激酶受体(RTK)家族中的一员,与其配体干细胞因子结合后受体酪氨酸激酶功能区被激活,产生自身磷酸化,完成细胞内外的信号传导,对这些细胞的分化发育以及功能维持起重要作用。近年来研究发现小细胞肺癌(SCLC)存在c-kit蛋白受体的异常高表达,推测其突变与SCLC发生存在着一定的联系,本文综述了c-kit蛋白受体在SCLC研究中的进展。小细胞肺癌是高侵袭性疾病,其在所有肺癌的诊断中约占15%²0%,其特点是肿瘤倍增时间快、生长分数高、播散转移早,对一线化学治疗(化疗)和放射治疗(放疗)高度敏感,但是无论疾病程度如何,绝大多数患者最终化疗后会发生疾病复发或化疗耐受,使SCLC化疗后维持治疗成为研究重点。目前,新的靶向药物在临床中的研究让我们看到了方向,分子靶向治疗可能成为化疗后维持治疗的最有效疗法。本文提供了一例舒尼替尼在小细胞肺癌患者化疗后维持治疗的病例,旨在为SCLC化疗后维持治疗提供新的思路。

Expression of c-kit protein in small cell lung cancer and exploration of the maintenance treatment ;after chemotherapy for small cell lung cancer

C-kit is a member of the receptor tyrosine kinase subclassⅢfamily. Stem cell factor （SCF） is the cognate ligand for c-kit. When c-kit binds to SCF, the function area of receptor tyrosine kinase will be activated, to complete signal transduction pathways and then play a role in the cell functions including survival, proliferation and adhersion. Recently some studies argue that there is c-kit abnormal high expression in small cell lung cancer （SCLC）, and the kinase activity of kit has been implicated in the pathophysiology of SCLC. This article reviewed the study about the potential relationship between c-kit protein and SCLC. SCLC is a highly aggressive disease and represents approximately 15%-20% of all diagnosed lung cancers. Treatment of SCLC remains challenging because of its rapid growth, early dissemination, and development of drug resistance during the course of the disease. SCLC is highly sensitive to radiotherapy and chemotherapy, however, no matter the extent of disease, most of patients will have tumor recurrence or resistance to the chemotherapy in the end, so it’s very important to study the maintenance treatment after chemotherapy for the patients of SCLC. Currently, new targeted drugs have offered several prospects in clinical studies. The most significant advance in the treatment of this challenging disease may be the introduction of molecularly targeted therapies. In this article, we provided a case about the application of sunitinib in SCLC, aimed to investigate a new method about the maintenance treatment after chemotherapy in SCLC.